# Puerarin Versus Atorvastatin in Treating Metabolism Syndrome in Patients With Chronic Rheumatic Diseases

> **NCT02219191** · NA · UNKNOWN · sponsor: **Chengdu PLA General Hospital** · enrollment: 150 (estimated)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** puerarin tablet 50 mg
- **DRUG:** Atorvastatin tablet 20 mg

## Key facts

- **NCT ID:** NCT02219191
- **Lead sponsor:** Chengdu PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-08
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2017-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02219191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02219191, "Puerarin Versus Atorvastatin in Treating Metabolism Syndrome in Patients With Chronic Rheumatic Diseases". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02219191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*